Japan-headquartered pharmaceutical firm Eisai Co. has announced that its US subsidiary Eisai Inc. has decided to invest up to $15 million in US-based C₂N Diagnostics LLC to support C₂N's efforts to expand the availability, accessibility, affordability and utilisation of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the US.

This investment is in addition to the collaboration with C₂N announced in August 2022 regarding the use of blood-based assays in the diagnosis of people living with dementia in clinical practice in the US.

The presence of amyloid β (Aβ), a component of AD pathology, is currently confirmed using advanced diagnostic techniques such as positron emission tomography (PET) or by tests that require the collection of cerebrospinal fluid (CSF).

By investing in C₂N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.

Using multiple approaches, Eisai collaborates with several diagnostic companies and with local governments to expand the dementia ecosystem. This investment and Eisai's collaboration with C₂N are examples of such activities.